GlaxoSmithKline Biologicals Group of Companies, Wavre, Belgium.
Independent Consultant, Brisbane, Australia.
Epidemiol Infect. 2011 Jul;139(7):967-85. doi: 10.1017/S0950268811000574. Epub 2011 Apr 15.
A literature search traced existing information on meningococcal disease in Asia. Reviewed data describing the epidemiology of meningococcal disease in Asia are incomplete, due in part to absence of surveillance in many countries, poor bacterial detection methods and social and healthcare barriers to disease reporting. This suggests that meningococcal disease in some Asian countries may be under-recognized, with a need to introduce/improve existing surveillance and case identification systems. Nevertheless, in some developing Asian countries, the disease burden may be significant. Serogroup A meningococcal epidemics are responsible for high morbidity and mortality in some countries and continue to be an ongoing threat, particularly in developing countries. There is an increasing role played by serogroups C, Y, and W-135 in invasive disease, indicating evolving meningococcal disease epidemiology in some countries. Multivalent meningococcal conjugate vaccines offer new opportunities in the region for reducing the meningococcal disease burden.
一项文献检索追溯了亚洲地区脑膜炎球菌病的现有信息。由于许多国家缺乏监测、细菌检测方法不佳以及社会和医疗保健对疾病报告的障碍，描述亚洲脑膜炎球菌病流行病学的数据并不完整。这表明，一些亚洲国家的脑膜炎球菌病可能未被充分认识，需要引入/改进现有的监测和病例识别系统。然而，在一些亚洲发展中国家，疾病负担可能很沉重。A 群脑膜炎球菌流行在一些国家造成了高发病率和死亡率，仍然是一个持续的威胁，特别是在发展中国家。C、Y 和 W-135 群在侵袭性疾病中的作用日益增加，表明一些国家的脑膜炎球菌病流行病学正在发生变化。多价脑膜炎球菌结合疫苗为该地区减少脑膜炎球菌病负担提供了新的机会。
